CD52、CD22、CD26、EG5和IGF-1R在胸腺恶性肿瘤中的表达

CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

作者信息

Remon J, Abedallaa N, Taranchon-Clermont E, Bluthgen V, Lindsay C R, Besse B, Thomas de Montpréville V

机构信息

Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France.

Departement d'Anatomie Pathologiques Recherche, Institut Universitaire du Cancer Toulouse - Oncopole, 1 Avenue Irène Joint-Curie, 31509 Toulouse Cedex 9, France.

出版信息

Lung Cancer. 2017 Jun;108:168-172. doi: 10.1016/j.lungcan.2017.03.019. Epub 2017 Mar 31.

DOI:10.1016/j.lungcan.2017.03.019

PMID:28625631

Abstract

BACKGROUND

Thymic epithelial tumours are rare cancers for which new treatment options are required. Identification of putative predictive markers is important for developing clinical trials. We studied the expression of five putative predictive biomarkers, potentially actionable by approved experimental drugs.

METHODS

CD52, CD22, CD26, EG5, and IGF-1R expression were investigated by immunohistochemistry in formalin-fixed surgical samples of thymic epithelial tumour patients. All samples containing 10% positive epithelial tumour cells, independent of tumour cell intensity, were considered as positive. Correlation with histological subtype was performed.

RESULTS

106 surgical samples (89 thymomas, 12 thymic carcinoma, and 5 thymic neuroendocrine tumours) were evaluated. Overall, CD52, CD22, CD26, EG5 and IGF-1R expression was observed in 7%, 42%, 25%, 42% and 77% of samples, respectively. CD52 expression was more frequent in B2 and B3 thymoma. All TET subtypes stained for CD22, mainly AB thymoma (68%). CD26 expression also correlated with AB thymoma (68%), and A thymoma (50%) subtype, while IGFR1 was the most common marker expressed by thymic carcinoma samples (92%), followed by EG5 (60%). Only EG5 expression was significantly higher in thymic carcinomas than in thymomas (75% vs. 38%, p=0.026).

CONCLUSIONS

Our data were consistent with a previous study of IGF-1R expression. Based on their expression, activity of agents targeting CD52, CD 22, CD26 and EG5 could be further explored in TET patients.

摘要

背景

胸腺上皮肿瘤是罕见癌症，需要新的治疗选择。确定假定的预测标志物对于开展临床试验很重要。我们研究了五种假定的预测生物标志物的表达，这些标志物可能可通过已批准的实验药物发挥作用。

方法

采用免疫组织化学方法，对胸腺上皮肿瘤患者福尔马林固定的手术样本中CD52、CD22、CD26、EG5和IGF-1R的表达进行研究。所有含有10%阳性上皮肿瘤细胞的样本，无论肿瘤细胞强度如何，均视为阳性。分析其与组织学亚型的相关性。

结果

共评估了106份手术样本（89例胸腺瘤、12例胸腺癌和5例胸腺神经内分泌肿瘤）。总体而言，分别在7%、42%、25%、42%和77%的样本中观察到CD52、CD22、CD26、EG5和IGF-1R的表达。CD52表达在B2和B3胸腺瘤中更常见。所有胸腺瘤-胸腺癌（TET）亚型均表达CD22，主要是AB型胸腺瘤（68%）。CD26表达也与AB型胸腺瘤（68%）和A型胸腺瘤（50%）亚型相关，而IGFR1是胸腺癌样本中最常见的表达标志物（92%），其次是EG5（60%）。仅EG5在胸腺癌中的表达显著高于胸腺瘤（75%对38%，p=0.026）。